Showing 2431-2440 of 2656 results for "".
- Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRShttps://modernod.com/news/eyenovia-announces-presentation-of-successful-phase-3-studies-at-the-ascrs/2476557/Eyenovia announced the safety and efficacy results from the company’s two phase 3 trials, MIST-1 and MIST-2, for pharmacologic mydriasis (pupil dilation). The results were presented by David Wirta, MD, from the podium during the joint ASCRS-ASOA annual meeting, on May 5, 2019 in S
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data
- Avellino Labs to Provide Corporate and Technology Updates at OIS and ASCRS in San Diegohttps://modernod.com/news/avellino-labs-to-provide-corporate-and-technology-updates-at-ois-and-ascrs-in-san-diego/2476522/Executives from Avellino Labs will be presenting at several events during the American Society of Cataract and Refractive Surgery annual meeting at the San Diego Convention Center and nearby venues, May 2-5, 2019. Known for its successful introduction of the world’s first DNA test to
- Roche Further Extends Tender Offer for Spark Therapeutics as FTC Review Continueshttps://modernod.com/news/roche-further-extends-tender-offer-for-spark-therapeutics-as-ftc-review-continues/2476508/Roche said Friday that it is extending its offer period related to the proposed acquisition of Spark Therapeutics for a second time to give the US Federal Trade Commission (FTC) more time to review the deal, according to FirstWord. Roche noted that the FTC’s “review of the transaction
- Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During ASCRShttps://modernod.com/news/bausch-lomb-announces-new-scientific-analyses-featuring-surgical-and-pharmaceutical-products-will-be-presented-during-ascrs/2476509/Bausch + Lomb announced that 26 new scientific analyses, including 23 podium presentations and three posters, will feature the company’s surgical and pharmaceutical products during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr
- Novaliq and BLP Management Group Establish New Company, Betaliq, to Leverage EyeSol Technology to Treat Glaucomahttps://modernod.com/news/novaliq-and-blp-management-group-establish-new-company-betaliq-to-leverage-eyesol-technology-to-treat-glaucoma/2476500/Novaliq and BLP Management group announced the formation and funding of Betaliq. The Tampa-based company’s pipeline consists of two preservative-free glaucoma drug candidates based on new in class and best in class ß-blocker molecules using Novaliq’s waterfree EyeSol technology. Two EyeSol-
- Allergan to Showcase New Data at ARVOhttps://modernod.com/news/allergan-to-showcase-new-data-at-arvo/2476496/Allergan will present new data at the Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) to be held in Vancouver, British Columbia from April 28 – May 2. Data will include three paper presentations on the company’s ophthalmology pipeline including
- Foundation Fighting Blindness to Host Annual Retinal Cell & Gene Therapy Innovation Summit Before ARVOhttps://modernod.com/news/foundation-fighting-blindness-to-host-annual-retinal-cell-gene-therapy-innovation-summit-before-arvo/2476488/The Foundation Fighting Blindness will co-host the 6th annual Retinal Cell and Gene Therapy Innovation Summit, in partnership with the Casey Eye Institute at Oregon Health & Science University. The summit–one of the world’s most comprehensive reviews (three dozen presenters) of ongoing
- Novartis Announces FDA BLA Acceptance of Brolucizumab for Wet AMDhttps://modernod.com/news/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-for-wet-amd/2476468/Novartis announced that the FDA has accepted the company’s biologics license application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD). Novartis used a priority review voucher to expedite FDA review and anticipates launching brolucizumab, if